This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the standard conventional high frequency left sided stimulation protocol. The Left dorsolateral prefrontal cortex will be the site of stimulation in both treatment conditions. The site of stimulation will be targeted using MRI co-registration.
The objectives of this 15-day study are:
This study aims to determine whether body weight-supported treadmill training (BWSTT) has beneficial effects, over and above arm-cycle ergometry training (ACET) on indicators of cardiovascular disease (CVD) risk in individuals with severe spinal cord injury (SCI).
The purpose of this study is to verify the clinical benefit of aducanumab compared with placebo in participants with Alzheimer’s disease, including those with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.
The purpose of this study is to evaluate the effectiveness and safety of a spinal cord neuromodulation (SCONE) therapy in improving symptoms of neurogenic lower urinary tract dysfunction, as compared to an inactive sham control.
The purpose of this study is to determine if the use of colchicine, a drug that reduces inflammation, can lower the risk of having a stroke or heart attack from blood clots compared to placebo, and improve recovery in people with a recent brain bleed.
The purpose of this study is to test an educational program called Brain Health PRO. This program is designed to teach you about dementia risk factors. It will provide best available evidence for lifestyle changes that may help lower dementia risk, including exercise, nutrition, sleep, and social and psychological health.
The purpose of this study is to create an adaptive clothing guide (FashionABLE) with an open-source library of clothing hacks and newly developed patterns of adaptive clothing that offers diverse, appropriate and fashion-forward clothing options that meet the functional and social needs of persons with spinal cord injury.
The purpose of this study is to investigate changes in the brain in people affected by Parkinson’s disease using PET and fMRI imaging.
The purpose of this study is to explore the use of bright light therapy as maintenance treatment for depression to determine if it is
The purpose of this study is to learn about biomarkers (biological features such as proteins, genes, and brain images that indicate the state of a disease in a person), and how they can help predict treatment outcomes in patients with clinical depression.
The purpose of this study is to evaluate the safety and efficacy of the drug ravulizumab for the treatment of participants with generalized myasthenia gravis.
The purpose of this study is to assess the efficacy and safety of CNM-Au8 as a remyelinating therapy in patients with stable relapsing-remitting multiple
sclerosis (RMS).
The purpose of this study is to assess the safety and tolerability of valbenazine for the treatment of chorea associated with Huntington's Disease.
The purpose of this study is to explore certain aspects of the blood and brain to determine how a person may recover from COVID-19. In addition, this study will examine how the different aspects of COVID-19 may affect how a person thinks or feels.
This is an observational study of patients with Primary Mitochondrial Disease with either signs or symptoms suggestive of myopathy.
The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.
There is a new theory that Parkinson's disease may start in the gut, but research is limited. The purpose of this study is to better understand the association between Parkinson's disease and the bacteria and fungi living in the gut and nose.
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment